Eli Lilly & Co.: Positive Long-Term Outlook Despite Recent Setbacks – Buy Rating Affirmed
Analyst Mohit Bansal from Wells Fargo maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and keeping the price target at ...
Eli Lilly & Co. stock underperforms Tuesday when compared to competitors
Shares of Eli Lilly & Co. LLY slipped 6.59% to $744.91 Tuesday, on what proved to be an all-around great trading session for ...
Eli Lilly: Big 2025 Ahead, But Execution Risks Exist
Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...
Eli Lilly & Co: Strong Growth Prospects and Strategic Positioning Justify Buy Rating
Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Evan ...
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Dropped on Tuesday
Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...
Eli Lilly CEO David Ricks: Projecting 32% total growth for company in 2025
Eli Lilly CEO David Ricks joins 'Squawk on the Street' to discuss the company's drug pipeline, 2025 outlook, state of the ...
BioSpace1d
Lilly Projects 2024 Revenue Miss as Zepbound, Mounjaro Disappoint
The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, ...
Eli Lilly and Company (LLY) CEO Dave Ricks presents at 43rd Annual J.P. Morgan Healthcare Conference (Transcript)
Eli Lilly and Company (NYSE:LLY) 43rd Annual J.P. Morgan Healthcare Conference January 14, 2025 5:15 PM ETCompany ParticipantsDave Ricks - Chairman ...
Medicare can cover Zepbound for sleep apnea, creating a significant opportunity for Eli Lilly
Zepbound is not covered by Medicare or many other insurance plans as a treatment for weight loss. The injectable treatment ...
FiercePharma1d
JPM25: Eli Lilly's preliminary '24 sales figures show a continued easing in breakneck GLP-1 market
Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...
Hosted on MSN14h
Eli Lilly Gets Wall Street Backing After Tuesday’s Turmoil, Stock Rises Premarket As Retail Stays Bullish
Eli Lilly & Co. (LLY) shares rose 0.3% premarket Wednesday, bouncing slightly after Tuesday's steep 6% plunge — the worst ...